Trial Profile
A Multicenter, Open-Label Study to Assess the Tolerability and Safety of a Single, Subcutaneous Administration of Ecallantide in Children and Adolescents With Hereditary Angioedema
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- 28 Mar 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 03 Jan 2017 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017.